High Risk, High Reward: Why Revolution Medicines Could Double From Here
Revolution Medicines (RVMD) is a speculative, clinical-stage oncology name that has re-rated sharply in 2026 after Breakthrough Therapy recognition for daraxonrasib and fresh institutional buying. The setup combines a binary regulatory/catalyst path with elevated short interest and a valuation that still reflects pre-revenue status. This trade idea…